БАЙ Шуан (US),ЧЭНЬ Дэниел С. (US),ФУНКЕ Рул (US),ХЕДЖД Прити (US),НАУМОВСКИ Луи (US)
申请号：
RU2013140471/15
公开号：
RU2013140471A
申请日:
2012.02.01
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating cancer in a patient comprising administering antibodies against EGFL7 the method comprises administering an antibody at a dose of 1 mg / kg to 15 mg / kg.2. A method of treating cancer in a patient comprising administering antibodies against EGFL7 the method comprises administering the antibody constant dose selected from the group consisting of: (a) 375-400 mg every two weeks, and (b) 550-600 mg every three nedeli.3. A method according to claim. 2, wherein a constant dose of 375-400 mg every two nedeli.4. A method according to claim. 2, wherein a constant dose of 550-600 mg every three nedeli.5. A method of treating cancer in a patient comprising administering antibodies against EGFL7 the method comprises administering the first dose of anti-EGFL7 patient and the second dose of anti-EGFL7 patient, wherein each of the first dose and the second dose is from 1 mg / kg to 15 mg / kg, and the second dose following the first dose at a time interval of from 1 to 4 nedel.6. The method of claim. 5, wherein each of the first dose and the second dose is from 5 mg / kg to 7.5 mg / kg, and the second dose following the first dose at a time interval of 2 to 3 nedel.7. A method according to claim. 6, wherein each first dose and a second dose of 5 mg / kg, and the second dose following the first dose with 2 nedeli.8 time interval. A method according to claim. 6, wherein each first dose and a second dose of 7.5 mg / kg, and the second dose following the first dose of from 3 nedeli.9 time interval. A method according to any one of claims. 1-8, wherein said anti-EGFL7 antibody comprises a variable domain comprising the following HVR sequences: (i) HVR-L1, containing KASQSVDYSGDSYMS (SEQ ID NO: 1) (ii) HVR-L2, comprising GASYRES (SEQ ID NO: 2) (iii) HVR-L3, comprising QQNNEEPYT (SEQ ID NO: 3) (iv) HVR-H1, comprising1. Способ лечения злокачественного новообразования у пациента, включающий введение антитела против EGFL7 способ включает введение антитела в дозе от
